1. Acknowledgement to Referees

   Acknowledgement to Referees 13 November 2018 Pages: 669 - 672

2. Annual Congress of the European Society for Medical Oncology (ESMO): Munich, Germany, 19–23 October 2018

   • Martin Chopra

   Meeting Report 13 November 2018 Pages: 673 - 677

3. Therapy of Advanced Prostate Cancer: Targeting the Androgen Receptor Axis in Earlier Lines of Treatment

   • Harsh Shah
   • Ulka Vaishampayan

   Review Article 07 December 2018 Pages: 679 - 689

   

4. New Horizons in the Treatment of Metastatic Pancreatic Cancer: A Review of the Key Biology Features and the Most Recent Advances to Treat Metastatic Pancreatic Cancer

   • Helena Verdaguer
   • Alvaro Arroyo
   • Teresa Macarulla

   Review Article 23 November 2018 Pages: 691 - 704

   

5. Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy

   • Francesco Massari
   • Vincenzo Di Nunno
   • Camillo Porta

   Systematic Review 15 October 2018 Pages: 705 - 714

   

6. Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study

   • Vasilios Karavasilis
   • Epaminontas Samantas
   • George Fountzilas

   Original Research Article 28 November 2018 Pages: 715 - 724

   

7. Real-World Use and Outcomes of Olaparib: a Population-Based Cohort Study

   • Irene Eriksson
   • Björn Wettermark
   • Kjell Bergfeldt

   Original Research Article Open access 16 November 2018 Pages: 725 - 733

   

8. Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis

   • Ondrej Fiala
   • Veronika Veskrnova
   • Tomas Buchler

   Original Research Article 23 October 2018 Pages: 735 - 743

   

9. Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma

   • Hiroki Ishihara
   • Toshio Takagi
   • Kazunari Tanabe

   Original Research Article 16 October 2018 Pages: 745 - 755

   

10. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy

    • Xia Yang
    • Jia Rao
    • Ruohong Shui

    Original Research Article Open access 07 November 2018 Pages: 757 - 767

    

11. PD-1 and PD-L1 Expression in Male Breast Cancer in Comparison with Female Breast Cancer

    • Quirine F. Manson
    • Natalie D. ter Hoeve
    • Paul J. van Diest

    Original Research Article Open access 05 December 2018 Pages: 769 - 777

    

12. Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib

    • Lucy Swift
    • Aarthi Jayanthan
    • Aru Narendran

    Original Research Article 16 November 2018 Pages: 779 - 793

    

13. Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy

    • Giovanni Fucà
    • Giulia Galli
    • Diego Signorelli

    Short Communication 10 October 2018 Pages: 795 - 800

    

14. Olaparib Tablet: A Review in Ovarian Cancer Maintenance Therapy

    • Young-A Heo
    • Sohita Dhillon

    Adis Drug Evaluation 20 November 2018 Pages: 801 - 808